- Home
- AKRO vs BLTE Comparison
AKRO vs BLTE Comparison
Compare AKRO & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- BLTE
- Stock Information
- Founded
- AKRO 2017
- BLTE 2018
- Country
- AKRO United States
- BLTE United States
- Employees
- AKRO N/A
- BLTE N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- BLTE Health Care
- Exchange
- AKRO Nasdaq
- BLTE Nasdaq
- Market Cap
- AKRO 2.4B
- BLTE 2.1B
- IPO Year
- AKRO 2019
- BLTE 2022
- Fundamental
- Price
- AKRO $28.09
- BLTE $82.81
- Analyst Decision
- AKRO Strong Buy
- BLTE Strong Buy
- Analyst Count
- AKRO 7
- BLTE 4
- Target Price
- AKRO $43.20
- BLTE $89.00
- AVG Volume (30 Days)
- AKRO 617.2K
- BLTE 110.7K
- Earning Date
- AKRO 11-08-2024
- BLTE 11-12-2024
- Dividend Yield
- AKRO N/A
- BLTE N/A
- EPS Growth
- AKRO N/A
- BLTE N/A
- EPS
- AKRO N/A
- BLTE N/A
- Revenue
- AKRO N/A
- BLTE N/A
- Revenue This Year
- AKRO N/A
- BLTE N/A
- Revenue Next Year
- AKRO N/A
- BLTE N/A
- P/E Ratio
- AKRO N/A
- BLTE N/A
- Revenue Growth
- AKRO N/A
- BLTE N/A
- 52 Week Low
- AKRO $14.41
- BLTE $31.01
- 52 Week High
- AKRO $37.00
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- AKRO 38.58
- BLTE 73.39
- Support Level
- AKRO $31.12
- BLTE $77.62
- Resistance Level
- AKRO $35.11
- BLTE $86.53
- Average True Range (ATR)
- AKRO 1.99
- BLTE 5.84
- MACD
- AKRO -0.53
- BLTE 0.69
- Stochastic Oscillator
- AKRO 11.68
- BLTE 88.01
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.